In vitro co-delivery evaluation of novel pegylated nano-liposomal herbal drugs of silibinin and glycyrrhizic acid (Nano-phytosome) to hepatocellular carcinoma cells

Cell Journal

Volumn 18, Issue 2, 2016, Pages 135-148

  Ochi, Mohammad Mahdi ^a   Amoabediny, Ghasem ^a   Rezayat, Seyed Mahdi ^b   Akbarzadeh, Azim ^a,c   Ebrahimi, Bahman ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Encapsulation; Glycyrrhizic acid; Hepatocellular carcinoma; Silibinin

Indexed keywords

CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; GLYCYRRHIZIC ACID; LIPOSOME; MACROGOL 2000; NANO PHYTO LIPOSOME; SILIBININ; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FIBROBLAST; HEPG2 CELL LINE; IC50; IN VITRO STUDY; NANOENCAPSULATION;

EID: 84976892339     PISSN: 22285806     EISSN: 22285814     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jin C, Yang W, Bai L, Wang J, Dou K. Preparation and characterization of targeted DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F (ab') 2 for treatment of hepatocellular carcinoma. J Control Release. 2011; 152 Suppl 1: e14-15.
2. Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2008; 126(1): 50-58.
3. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015; 10: 975-999.
4. Rathore P, Swami G. Planterosomes: a potential phytophospholipid carriers for the bioavailability enhancement of herbal extracts. Int J Pharm Sci Res. 2012; 3(3): 737-755.
5. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther. 2007; 6(2): 104-109.
6. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidyl-choline complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990; 15(4): 333-338.
7. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung. 1992; 42(7): 964-968.
8. Chen MW, Tan W, Wang ShP, Zhong ZhF, Wang YT. Advances in the nanoparticle drug delivery systems of silymarin. J Chin Pharm Sci. 2011; 20(5): 442-446.
9. Radjabian T, Fallah Huseini H. Anti-hyperlipidemic and anti-atherosclerotic activities of silymarins from cultivated and wild plants of silybum marianum L. with different content of favonolignans. Iranian J pharmacol Ther. 2010; 9(2): 63-67.
10. Ramakrishnan G, Raghavendran HR, Vinodhkumar R, Devaki T. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem Biol Interact. 2006; 161(2): 104-114.
11. Gažák R, Marhol P, Purchartová K, Monti D, Biedermann D, Riva S, et al. Large-scale separation of silybin diastereoisomers using lipases. Process Biochem. 2010; 45(10): 1657-1663.
12. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004; 40(3): 143-149.
13. Song Y, Zhuang J, Guo J, Xiao Y, Ping Q. Preparation and properties of a silybin-phospholipid complex. Pharmazie. 2008; 63(1): 35-42.
14. El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm. 2006; 308(1-2): 140-148.
15. Archakov AI, Guseva MK, Uchaikin VF, Tikhonova EG, Ipatova OM. Medicinal forms of phospholipid preparations and methods for their preparation. United States Patent (USPTO). Publication type of patent: grant. 2014; Available from: http://www.google.com/patents/US8680061 (5 Apr 2016).
16. Park JH, Park JH, Hur HJ, Woo JS, Lee HJ. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats. Eur J Pharm Sci. 2012; 45(3): 296-301.
17. Ren P, Sun G. HPLC determination of glycyrrhizic acid and glycyrrhetinic acid in fuzilizhong pills. Asian J Trad Med. 2008; 3(3): 110-116.
18. Bombardelli E, Cristoni A, Morazzoni P. Phytosomes in functional cosmetics. Fitoterapia. 1994, 65(5): 387-401.
19. Tedesco D, Steidler S, Galletti S, Tameni M, Sonzogni O, Ravarotto L. Efficacy of silymarin-phospholipid complex in reducing the toxicity of aflatoxin B1 in broiler chicks. Poult Sci. 2004; 83(11): 1839-1843.
20. Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin - phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm. 2006; 307(1): 77-82.
21. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 2006; 26(6B): 4457-4498.
22. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992; 1113(2): 171-199.
23. Nunes SS, Barros ALB The use of coating agents to enhance liposomes blood circulation time. J Mol Pharm Org Process Res. 2015; 3(1): 1-2.
24. Bagherpour Doun SK, Alavi SE. Koohi Moftakhari Esfahani M, Ebrahimi Shahmabadi H, Alavi F, Hamzei S. Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study. Tumor Biol. 2014; 35(8): 7491-7497.
25. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002; 8(11): 3512-3519.